MEWIGEN runs a molecular genetic laboratory located in Dresden, a growing research hot spot in Germany. As founders have its personal roots in genomic and tumor research itself (see reference list), MEWIGEN provides a wide range of molecular genetic services related to human and tumor genetics for health care professionals successfully now for more than 10 years.

Our services include Sanger Sequencing of more than 600 genes of the human genome associated with hereditary diseases and of many more genes in diverse diagnostic panels by Next Generation Sequencing (NGS). Moreover, we offer cDNA analyses for the clarification of potential splice site mutations, fluorescence-based fragment length analyses (microsatellites, various trinucleotide repeat expansions such as Huntington’s and Ataxias) as well as analyses for gross genomic deletions and duplications and aberrant methylation of relevant sites. The range of our diagnostic spectrum is continuously expanded.

As part of the Federal Ministry of Education and Research (BMBF)-funded innovative growth core PRÆMED.BIO MEWIGEN is working on the identification of therapy-relevant biomarkers for head and neck (HNSCC) and rectal cancer. For this purpose we establish detection of markers in circulating tumor DNA (ctDNA). Challenges of such analyses result from both, the low amount of cell free DNA (cfDNA) and the low proportion of circulating tumor DNA (ctDNA) in the cfDNA.The technique allows sampling of information during surveillance periods (appearance of resistance mutations and disease relapse) and further possibilities in a non-invasive way (e.g. early recognition of disease, choice of therapy).